标签归档：ew

EW设计PCR8联管/PCR 八联排PCR001-8F

发表于由

EW设计PCR8联管/PCR 八联排

  • 产品型号：PCR001-8F
  • 简要描述：EW设计PCR8联管/PCR 八联排金畔生物供应：光度计，检测仪，免疫仪，全系荧光定量PCR耗材，PCR八联管，进口PCR板，移液器，钻石吸嘴，离心管，冻存管，培养皿，培养板，培养瓶，吸头，仪器及手套，色谱耗材，针头过滤器。
产品咨询在线客服
  • 产品简介

EW设计PCR8联管/PCR 八联排金畔生物公司供应：ELISA试剂盒,动物血清,荧光定量PCR耗材,移液器吸嘴,微量离心管,进口冻存管,细胞培养皿,培养板,培养瓶,进口吸头,仪器及手套,色谱耗材,针头过滤器,分光光度计。

8联管 PCR八联排

货号        产品名称

PCR001-8F PCR 8联管；0.1ml；平盖；透明
PCR001-8C PCR 8联管；0.1ml；凸盖；透明
PCR001-8FD PCR 8联管；0.1 ml；连盖；透明
PCR001-8FW PCR 8联管；0.1ml；平盖；白色
PCR002-8F PCR 8联管；0.2 ml；平盖；透明
PCR002-8C PCR 8联管；0.2 ml；凸盖；透明
PCR002-8FD PCR 8联管；0.2 ml；连盖；透明
PCR002-8FW PCR 8联管；0.2 ml；平盖；白色
PCR002-12F PCR 8联管；0.2 ml；平盖；透明
PCR005-4C PCR 4联管；0.5ml；凸盖；透明
PCR001N-8F Bioland™ EW设计PCR8联管；0.1ml；平盖；透明
PCR001N-8FW Bioland™ EW设计PCR8联管；0.1ml；平盖；白色
PCR002N-8F Bioland™ EW设计PCR8联管；0.2 ml；平盖；透明
PCR002N-8FW Bioland™ EW设计PCR8联管；0.2 ml；平盖；白色

规格：125条/盒；10盒/箱

EW设计PCR8联管/PCR 八联排

加长带滤芯吸头袋装/盒装

进口加长吸头1000ul带滤芯

标准吸头/加长吸头适用于艾本德移液器

 

Bioland™ EW设计PCR 12联管;0.1 ml;平盖;透明

Bioland™ EW设计PCR 12联管;0.1 ml;平盖;白色

Bioland™ EW设计PCR 12联管;0.2 ml;平盖;透明

Bioland™ EW设计PCR 12联管;0.2 ml;平盖;白色

PCR 96孔板;0.1ml;无裙边;透明

PCR 96孔板PCR 96孔板;0.1ml;半裙边;透明

PCR 96孔板0.1ml;无裙边;白色

PCR 96孔板0.1ml;半裙边;白色

PCR 96孔板;0.2ml;无裙边;透明

PCR 96孔板;0.2ml;半裙边;透明

PCR 96孔板;0.2ml;无裙边;白色

PCR 96孔板;0.2ml;半裙边;白色

PCR 384孔板;带裙边;透明

PCR 384孔板;带裙边;白色

25cm2细胞培养瓶;滤膜盖;TC处理;无菌、无酶、无热原

25cm2细胞培养瓶;密封盖;TC处理;无菌、无酶、无热原

适应客户：医院检验科PCR实验室，中心实验室，肝病中心；第三方检测机构，科研院所，大专院校，制药厂，试剂生产厂家，疾控中心，检验检疫。 

EW设计PCR8联管/12联管PCR001N-8F

发表于由

EW设计PCR8联管/12联管

  • 产品型号：PCR001N-8F
  • 简要描述：EW设计PCR8联管/12联管金畔生物公司供应：ELISA试剂盒,分光光度计，血清，荧光定量PCR耗材，移液器吸嘴，微量离心管，进口冻存管，细胞培养皿，培养板，培养瓶，吸头，仪器及手套，色谱耗材，针头过滤器。
产品咨询在线客服
  • 产品简介

EW设计PCR8联管/12联管金畔生物公司供应：elisa试剂盒,动物血清,荧光定量PCR耗材,移液器吸嘴,微量离心管,进口冻存管,细胞培养皿,培养板,培养瓶,进口吸头,仪器及手套,色谱耗材,针头过滤器,分光光度计。

推出的EW设计PCR8联管

具有：

更易盖合

更易打开

液体无飞溅

有效保证实验安全
EW设计PCR8联管/12联管

EW设计PCR8联管

订货号

描述

包装

PCR001N-8F

EW设计PCR8联管；0.1ml；平盖；透明

125条/盒；10盒/箱

PCR001N-8FW

EW设计PCR8联管；0.1ml；平盖；白色

125条/盒；10盒/箱

PCR002N-8F

EW设计PCR8联管；0.2 ml；平盖；透明

125条/盒；10盒/箱

PCR002N-8FW

EW设计PCR8联管；0.2 ml；平盖；白色

125条/盒；10盒/箱

 EW设计PCR 12联管

订货号

描述

包装

PCR001N-12F

EW设计PCR 12联管；0.1 ml；平盖；透明

125条/盒；10盒/箱

PCR001N-12FW

EW设计PCR 12联管；0.1 ml；平盖；白色

125条/盒；10盒/箱

PCR002N-12F

EW设计PCR 12联管；0.2 ml；平盖；透明

125条/盒；10盒/箱

PCR002N-12FW

EW设计PCR 12联管；0.2 ml；平盖；白色

125条/盒；10盒/箱

方孔存储板 深孔板
适应客户：医院检验科PCR实验室，中心实验室，肝病中心；第三方检测机构，科研院所，大专院校，制药厂，试剂生产厂家，疾控中心，检验检疫。

东西分析便携式光离子化气体检测仪EW-4400

发表于由

东西分析便携式光离子化气体检测仪EW-4400

  • 品牌 东西分析|EWAI
  • 型号 EW-4400
  • 商品详情

    北京东西分析仪器有限公司研制开发成功EW－4400型便携式光离子化气相色谱仪,成为国内少有的产业化生产便携式光离子化气相色谱仪的生产厂商之一。该产品具有我国自主知识产权和特色。

    该色谱仪是一种集光谱学、电真空技术、精密机械、新材料、新工艺、电子学、集成电路、计算机、色谱分析等多种学科交叉为一体的高科技产品。

    该产品使用长寿命真空紫外光源，具有灵敏度高、检出限低、线性范围宽等特点，并且分析时无需氢气、助燃气体、任何化学试剂，无需样品前处理。既能用于有机化合物，又可对部分无机化合物进行痕量分析。由于灵敏度高，在分析室内外环境气体时，不需热解吸装置，可直接进样分析。

    这种便携式光离子化气相色谱仪其主要性能指标达到了国外同类产品的领先水平。

    该仪器的研制也是科技部2005年度科技型企业技术创新基金重点支持项目之一。使用方便、分析速度快、灵敏度高，克服了传统分析方法速度慢、前处理繁琐等特点。

    应用范围：
    环境保护、居室内环境污染监测、食品安全、国防防化与反恐战争、航空航天、科学研究与新产品开发等领域，及其他要求痕量气（汽）体分析的部门。

    主要特点:
    1、利用光子实现样品离子化,无放射源
    2、灵敏度高、检出限低、线性范围宽
    3、仪器重量轻，机动灵活，尤其适于现场分析和环境污染事故应急检测
    4、无需氢气、助燃气体，可用高纯氮气或空气作载气，内置载气瓶
    5、非破坏性检测、安全可靠
    6、水中有机挥发物分析，顶空取样直接进样检测
    7、无需化学前处理、浓缩、富集、吸附-热解吸。直接进样分析，结果准确、可靠
    8、由数据采集器、笔记本电脑及相应软件构成的色谱工作站，进行数据采集、分析、计算、显示、存储

    • EW-7195

    发表于由

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

    EW-7195 

    EW-7195 是一种有效的、选择性 ALK5 (TGFβR1) 抑制剂，IC50 为 4.83 nM。EW-7195 对 ALK5 的选择性是 p38α 的 300 多倍。EW-7195 能有效抑制 TGF-β1 诱导的 Smad 信号转导、上皮间质转化 (EMT) 和乳腺癌向肺转移。

    EW-7195

    EW-7195 Chemical Structure

    CAS No. : 1352609-28-9

    规格 是否有货
    100 mg   询价  
    250 mg   询价  
    500 mg   询价  

    * Please select Quantity before adding items.

    生物活性

    EW-7195 is a potent and selective ALK5 (TGFβR1) inhibitor with an IC50 of 4.83 nM. EW-7195 has >300-fold selectivity for ALK5 over p38α. EW-7195 efficiently inhibits TGF-β1-induced Smad signaling, epithelial-to-mesenchymal transition (EMT) and breast tumour metastasis to the lung[1].

    IC50 & Target[1]

    ALK5

    4.83 nM (IC50)

    p38α

    1.5 μM (IC50)

    体外研究
    (In Vitro)

    EW7195 inhibits the EMT, motility, and invasiveness of breast cancer cells in vitro. EW-7195 efficiently blocks TGF-β1-induced phosphorylation of Smad2 followed by the nuclear translocation of Smad2/3. EW-7195 blocks TGF-β1-induced mesenchymal morphology. EW-7195 inhibits TGF-β-induced transcriptional activation[1].
    EW-7195 (0.5-1 µM; 1.5 hours) efficiently inhibits TGF-β1-induced Smad2 phosphorylation[1].

    Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
    体内研究
    (In Vivo)

    EW7195 (40 mg/kg; i.p.; three times a week for 3/2.5 weeks) inhibits lung metastasis development in both 4T1 orthotopic xenograft and MMTV/cNeu transgenic mice[1].

    Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: MMTV/c-Neu mice[1]
    Dosage: 40 mg/kg
    Administration: I.p.; three times a week for 3 weeks
    Result: Inhibited the metastasis of breast cancer cells to the lung.
    Animal Model: Balb/c xenograft model (10-weeks-old female Balb/c mice bearing 4T1 cells)[1]
    Dosage: 40 mg/kg
    Administration: I.p.; three times a week for 2.5 weeks
    Result: Suppressed a lung metastasis in the Balb/c Xenograft model.

    分子量

    406.44

    Formula

    C23H18N8
    CAS 号

    1352609-28-9
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式

    Please store the product under the recommended conditions in the Certificate of Analysis.
    参考文献

    • [1]. Park CY, et al. EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung. Eur J Cancer. 2011;47(17):2642-2653.

    所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

    EW-7195

    发表于由

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

    EW-7195 

    EW-7195 是一种有效的、选择性 ALK5 (TGFβR1) 抑制剂，IC50 为 4.83 nM。EW-7195 对 ALK5 的选择性是 p38α 的 300 多倍。EW-7195 能有效抑制 TGF-β1 诱导的 Smad 信号转导、上皮间质转化 (EMT) 和乳腺癌向肺转移。

    EW-7195

    EW-7195 Chemical Structure

    CAS No. : 1352609-28-9

    规格 是否有货
    100 mg   询价  
    250 mg   询价  
    500 mg   询价  

    * Please select Quantity before adding items.

    生物活性

    EW-7195 is a potent and selective ALK5 (TGFβR1) inhibitor with an IC50 of 4.83 nM. EW-7195 has >300-fold selectivity for ALK5 over p38α. EW-7195 efficiently inhibits TGF-β1-induced Smad signaling, epithelial-to-mesenchymal transition (EMT) and breast tumour metastasis to the lung[1].

    IC50 & Target[1]

    ALK5

    4.83 nM (IC50)

    p38α

    1.5 μM (IC50)

    体外研究
    (In Vitro)

    EW7195 inhibits the EMT, motility, and invasiveness of breast cancer cells in vitro. EW-7195 efficiently blocks TGF-β1-induced phosphorylation of Smad2 followed by the nuclear translocation of Smad2/3. EW-7195 blocks TGF-β1-induced mesenchymal morphology. EW-7195 inhibits TGF-β-induced transcriptional activation[1].
    EW-7195 (0.5-1 µM; 1.5 hours) efficiently inhibits TGF-β1-induced Smad2 phosphorylation[1].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
    体内研究
    (In Vivo)

    EW7195 (40 mg/kg; i.p.; three times a week for 3/2.5 weeks) inhibits lung metastasis development in both 4T1 orthotopic xenograft and MMTV/cNeu transgenic mice[1].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: MMTV/c-Neu mice[1]
    Dosage: 40 mg/kg
    Administration: I.p.; three times a week for 3 weeks
    Result: Inhibited the metastasis of breast cancer cells to the lung.
    Animal Model: Balb/c xenograft model (10-weeks-old female Balb/c mice bearing 4T1 cells)[1]
    Dosage: 40 mg/kg
    Administration: I.p.; three times a week for 2.5 weeks
    Result: Suppressed a lung metastasis in the Balb/c Xenograft model.

    分子量

    406.44

    Formula

    C23H18N8
    CAS 号

    1352609-28-9
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式

    Please store the product under the recommended conditions in the Certificate of Analysis.
    参考文献

    • [1]. Park CY, et al. EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung. Eur J Cancer. 2011;47(17):2642-2653.

    所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

    EW-7195

    发表于由

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

    EW-7195 

    EW-7195 是一种有效的、选择性 ALK5 (TGFβR1) 抑制剂，IC50 为 4.83 nM。EW-7195 对 ALK5 的选择性是 p38α 的 300 多倍。EW-7195 能有效抑制 TGF-β1 诱导的 Smad 信号转导、上皮间质转化 (EMT) 和乳腺癌向肺转移。

    EW-7195

    EW-7195 Chemical Structure

    CAS No. : 1352609-28-9

    规格 是否有货
    100 mg   询价  
    250 mg   询价  
    500 mg   询价  

    * Please select Quantity before adding items.

    生物活性

    EW-7195 is a potent and selective ALK5 (TGFβR1) inhibitor with an IC50 of 4.83 nM. EW-7195 has >300-fold selectivity for ALK5 over p38α. EW-7195 efficiently inhibits TGF-β1-induced Smad signaling, epithelial-to-mesenchymal transition (EMT) and breast tumour metastasis to the lung[1].

    IC50 & Target[1]

    ALK5

    4.83 nM (IC50)

    p38α

    1.5 μM (IC50)

    体外研究
    (In Vitro)

    EW7195 inhibits the EMT, motility, and invasiveness of breast cancer cells in vitro. EW-7195 efficiently blocks TGF-β1-induced phosphorylation of Smad2 followed by the nuclear translocation of Smad2/3. EW-7195 blocks TGF-β1-induced mesenchymal morphology. EW-7195 inhibits TGF-β-induced transcriptional activation[1].
    EW-7195 (0.5-1 µM; 1.5 hours) efficiently inhibits TGF-β1-induced Smad2 phosphorylation[1].

    Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
    体内研究
    (In Vivo)

    EW7195 (40 mg/kg; i.p.; three times a week for 3/2.5 weeks) inhibits lung metastasis development in both 4T1 orthotopic xenograft and MMTV/cNeu transgenic mice[1].

    Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: MMTV/c-Neu mice[1]
    Dosage: 40 mg/kg
    Administration: I.p.; three times a week for 3 weeks
    Result: Inhibited the metastasis of breast cancer cells to the lung.
    Animal Model: Balb/c xenograft model (10-weeks-old female Balb/c mice bearing 4T1 cells)[1]
    Dosage: 40 mg/kg
    Administration: I.p.; three times a week for 2.5 weeks
    Result: Suppressed a lung metastasis in the Balb/c Xenograft model.

    分子量

    406.44

    Formula

    C23H18N8
    CAS 号

    1352609-28-9
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式

    Please store the product under the recommended conditions in the Certificate of Analysis.
    参考文献

    • [1]. Park CY, et al. EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung. Eur J Cancer. 2011;47(17):2642-2653.

    所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

    Vactosertib(Synonyms: EW-7197; TEW-7197)

    发表于由

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

    Vactosertib (Synonyms: EW-7197; TEW-7197) 纯度: 99.09%

    Vactosertib (EW-7197) 是一种有效的，具有口服活性且具有 ATP 竞争性激活素受体样激酶 5 (ALK5) 抑制剂，IC50 为 12.9 nM。Vactosertib 还以纳摩尔浓度抑制 ALK2 和 ALK4 (IC50 为 17.3 nM)。Vactosertib 具有强大的抗转移活性和抗癌作用。

    Vactosertib(Synonyms: EW-7197; TEW-7197)

    Vactosertib Chemical Structure

    CAS No. : 1352608-82-2

    规格 价格 是否有货 数量
    Free Sample (0.1-0.5 mg)   Apply now  
    10 mM * 1 mL in DMSO ￥880 In-stock
    5 mg ￥800 In-stock
    10 mg ￥1200 In-stock
    25 mg ￥2000 In-stock
    50 mg ￥3100 In-stock
    100 mg ￥4800 In-stock
    200 mg   询价  
    500 mg   询价  

    * Please select Quantity before adding items.

    Vactosertib 相关产品

    •相关化合物库:

    • Drug Repurposing Compound Library Plus
    • Clinical Compound Library Plus
    • Bioactive Compound Library Plus
    • Kinase Inhibitor Library
    • TGF-beta/Smad Compound Library
    • Anti-Cancer Compound Library
    • Clinical Compound Library
    • Drug Repurposing Compound Library
    • Reprogramming Compound Library
    • Anti-COVID-19 Compound Library
    • Orally Active Compound Library
    • Anti-Breast Cancer Compound Library
    • Anti-Pancreatic Cancer Compound Library
    • Angiogenesis Related Compound Library
    • Targeted Diversity Library
    • Rare Diseases Drug Library
    • Anti-Colorectal Cancer Compound Library

    生物活性

    Vactosertib (EW-7197) is a potent, orally active and ATP-competitive activin receptor-like kinase 5 (ALK5) inhibitor with an IC50 of 12.9 nM. Vactosertib also inhibits ALK2 and ALK4 (IC50 of 17.3 nM) at nanomolar concentrations. Vactosertib has potently antimetastatic activity and anticancer effect[1][2].

    IC50 & Target[1]

    ALK5

    12.9 nM (IC50)

    体外研究
    (In Vitro)

    Vactosertib (10-1000 nM; 30 minutes; 4T1 cells) treatment blocks the TGFβ-induced phosphorylation of Smad2 or Smad3 in a dose-dependent manner in 4T1 cells[1].
    Vactosertib suppresses the TGFβ-induced nuclear translocation of Smad2/3 in 4T1 cells and MCF10A cells. The IC50 value of Vactosertib on pSmad3 in 4T1 cells is 10-30 nM[1].
    Vactosertib abrogates TGFb1-induced tumor cell migration and invasion[1].
    TGFβ1 downregulated the mRNA level of CDH1 and upregulated the mRNA levels of FN1, HMGA2 (high-mobility group AT-hook 2), SNAI1, and SNAI2 (Snail family zinc finger 1 and 2, respectively). Moreover, Vactosertib abolishes the TGFβ1-induced effects on genes related to epithelial-to-mesenchymal transition (EMT)[1].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

    Western Blot Analysis[1]

    Cell Line: 4T1 cells
    Concentration: 10 nM, 30 µM, 50 nM, 100 µM, 300 nM, 500 nM, 1000 nM
    Incubation Time: 30 minutes
    Result: Blocked the TGFb-induced phosphorylation of Smad2 or Smad3 in a dose-dependent manner.

    体内研究
    (In Vivo)

    Vactosertib (40 mg/kg; intraperitoneal injection; every other day; for 10 weeks; MMTV/c-Neu female mice) treatment inhibits Smad/TGFβ signaling, cell migration, invasion, and lung metastasis in MMTV/c-Neu mice[1].
    Vactosertib also inhibits the epithelial-to-mesenchymal transition (EMT) in both TGFβ-treated breast cancer cells and 4T1 orthotopic-grafted mice. Furthermore, Vactosertib enhances cytotoxic T lymphocyte activity in 4T1 orthotopic-grafted mice and increased the survival time of 4T1-Luc and 4T1 breast tumor-bearing mice[1].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Mammary tumor virus (MMTV)/c-Neu female mice (32-week-old)[1]
    Dosage: 40 mg/kg
    Administration: Intraperitoneal injection; every other day; for 10 weeks
    Result: Inhibited Smad/TGFβ signaling, cell migration, invasion, and lung metastasis in MMTV/c-Neu mice.

    Clinical Trial

    分子量

    399.42

    Formula

    C22H18FN7
    CAS 号

    1352608-82-2
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    溶解性数据
    In Vitro: 

    DMSO : 100 mg/mL (250.36 mM; Need ultrasonic)

    配制储备液
    浓度 溶剂体积 质量 1 mg 5 mg 10 mg
    1 mM 2.5036 mL 12.5182 mL 25.0363 mL
    5 mM 0.5007 mL 2.5036 mL 5.0073 mL
    10 mM 0.2504 mL 1.2518 mL 2.5036 mL

    *

    请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
    储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

    In Vivo:

    请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

    ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
    分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

    • 1.

      请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: 2.5 mg/mL (6.26 mM); Suspended solution; Need ultrasonic

      此方案可获得 2.5 mg/mL (6.26 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

      以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

      将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

    • 2.

      请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

      Solubility: ≥ 2.5 mg/mL (6.26 mM); Clear solution

      此方案可获得 ≥ 2.5 mg/mL (6.26 mM，饱和度未知) 的澄清溶液。

      以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

      将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
    • 3.

      请依序添加每种溶剂： 10% DMSO    90% corn oil

      Solubility: ≥ 2.5 mg/mL (6.26 mM); Clear solution

      此方案可获得 ≥ 2.5 mg/mL (6.26 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

      以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

    *以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
    参考文献

    • [1]. Son JY et al. EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis, 2014 Jul, 13(7):1704-16.

      [2]. Naka K, et al. Novel oral transforming growth factor-β signaling inhibitor EW-7197 eradicates CML-initiating cells. Cancer Sci. 2016 Feb;107(2):140-8.

    所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务